Related Experiment Video
Updated: Oct 20, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells via Mediating
Qian Li1, Zhenglan Huang1, Yuhang Peng1
1Key Laboratory of Laboratory Medical Diagnostics Designated by the Ministry of Education, Department of Clinical Hematology, Chongqing Medical University, Chongqing, China.
Abstract:
Abnormal subcellular localization of proteins is an important cause of tumorigenesis and drug resistance. Chromosome region maintenance 1 (CRM1), the nuclear export regulator of most proteins, has been confirmed to be over-expressed in various malignancies and is regarded as an efficient target. But the potential role of the CRM1 cofactor RanBP3 (Ran Binding Protein 3) is left unrevealed in chronic myeloid leukemia (CML). Here, we first detected the level of RanBP3 in CML and found an elevated RanBP3 expression in CML compared with control. Then we used shRNA lentivirus to down-regulated RanBP3 in imatinib sensitive K562 cells and resistant K562/G01 cells and found RanBP3 silencing inhibited cell proliferation by up-regulating p21, induced caspase3-related cell apoptosis, and enhanced the drug sensitivity of IM in vitro. Notably, we observed that RanBP3 silencing restored imatinib sensitivity of K562 cells in NOD/SCID mice. Mechanistically, the nuclear aggregation of SMAD2/3 revealed that tumor suppressor axis (TGF-β)-SMAD2/3-p21 was the anti-proliferation program related to RanBP3 knockdown, and the decrease of cytoplasmic ERK1/2 caused by RanBP3 interference leaded to the down-regulation of anti-apoptosis protein p(Ser112)-BAD, which was the mechanism of increased cell apoptosis and enhanced chemosensitivity to imatinib in CML. In summary, this study revealed the expression and potential role of RanBP3 in CML, suggesting that targeting RanBP3 alone or combined with TKIs could improve the clinical response of CML.
Insights
Ran Binding Protein 3 (RanBP3) is elevated in chronic myeloid leukemia (CML). Silencing RanBP3 inhibits CML cell growth and restores imatinib sensitivity, offering a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Abnormal protein localization drives cancer and drug resistance.
- CRM1 is a known target, but its cofactor RanBP3's role in CML is unknown.
- RanBP3 is a CRM1 cofactor involved in nuclear export.
Purpose of the Study:
- To investigate the role of RanBP3 in chronic myeloid leukemia (CML).
- To determine if RanBP3 is a potential therapeutic target in CML.
Main Methods:
- Measured RanBP3 levels in CML patient samples.
- Utilized shRNA lentivirus to down-regulate RanBP3 in K562 and K562/G01 cells.
- Assessed cell proliferation, apoptosis, and drug sensitivity in vitro and in vivo (NOD/SCID mice).
Main Results:
- RanBP3 expression is elevated in CML.
- RanBP3 silencing inhibited proliferation, induced apoptosis, and enhanced imatinib sensitivity in CML cells.
- RanBP3 knockdown restored imatinib sensitivity in vivo.
Conclusions:
- RanBP3 plays a significant role in CML pathogenesis.
- Targeting RanBP3, alone or with TKIs, may improve CML treatment outcomes.
- RanBP3 silencing impacts the TGF-β-SMAD2/3-p21 and ERK1/2-BAD pathways.
Related Concept Videos
Negative Regulator Molecules
Abnormal Proliferation
Regulation of Nuclear Protein Sorting
The Intrinsic Apoptotic Pathway
MAPK Signaling Cascades
The Ras Gene
Ras is a...

